GSK (GSK) Set to Announce Earnings on Wednesday

GSK (NYSE:GSK) will post its quarterly earnings results before the market opens on Wednesday, October 30th. Analysts expect GSK to post earnings of $1.19 per share for the quarter. GSK has set its FY 2024 guidance at 1.710-1.740 EPS.Investors interested in registering for the company’s conference call can do so using this link.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The company had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.49 billion. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

GSK Price Performance

GSK opened at $37.52 on Monday. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.99. GSK has a 12-month low of $33.67 and a 12-month high of $45.92. The stock has a 50-day moving average price of $41.12 and a 200-day moving average price of $41.15. The stock has a market capitalization of $77.76 billion, a P/E ratio of 15.13, a PEG ratio of 1.23 and a beta of 0.65.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Shareholders of record on Friday, August 16th were given a dividend of $0.3843 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a yield of 4.10%. The ex-dividend date of this dividend was Friday, August 16th. GSK’s payout ratio is presently 62.10%.

Analyst Ratings Changes

GSK has been the subject of a number of analyst reports. Jefferies Financial Group raised their price objective on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Finally, Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GSK currently has a consensus rating of “Buy” and an average price target of $50.00.

Insider Activity

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was acquired at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 10.00% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.